Biora Therapeutics, Inc. — Operating Income by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/4b1ee12b-d759-47c6-9216-880599923032/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2023 | $-67.1M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-039423 |
| FY 2022 | $-61.8M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-010973 |
| FY 2021 | $-117.8M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-004791 |
| FY 2020 | $-107.6M | 2020-01-01 – 2020-12-31 | evidence 0000950170-22-004791 |
| FY 2019 | $-140.1M | 2019-01-01 – 2019-12-31 | evidence 0001564590-21-014182 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).